Novastra Therapeutics, OAP-101, OmniAntigen Platform, XIRT, ESMO Congress 2026, Phase 1 Clinical Trial, Advanced Melanoma, Anti-PD-1 Resistance, Cancer Immunotherapy,

CAMBRIDGE, Mass., October 13, 2026 Novastra Therapeutics announced that initial clinical data from an ongoing investigator-initiated Phase 1 study...